Ranbaxy
Ranbaxy reports Rs2,983 crore Q4 loss on US probe provisioning
23 Feb 2012
Even though its consolidated sales rose over 79 per cent over the last quarter of 2010, Ranbaxy Laboratories Ltd, has reported a net loss of Rs2,982.8 crore, mainly on provisioning related to a probe by the US justice department
Ranbaxy launches generic version of cholesterol-lowering drug Lipitor in Australia
21 Feb 2012
Ranbaxy today said it has become the first generic drug maker to sell the generic version of Pfizer's block-buster cholesterol-lowering drug Lipitor in Australia
Ranbaxy to pay $500 million to settle USFDA ban
21 Dec 2011
Ranbaxy to share Lipitor profits with Teva
02 Dec 2011
Teva today acknowledged that it has entered into a profit-sharing deal with Ranbaxy, but did not provide details of what it was doing to earn that money
US FDA lifts curbs on Ranbaxy's generic Lipitor sales
01 Dec 2011
The US FDA has lifted its curbs on sales of Ranbaxy Laboratories' generic version of Pfizer's blockbuster cholesterol drug Lipitor, whose patent expired yesterday
Pfizer, Ranbaxy sued over Lipitor price fixing in the US
10 Nov 2011
Pfizer and Ranbaxy have been sued for holding back a generic version of Pfizer’s cholesterol-lowering drug Lipitor in the US and then fixing its price.
Ranbaxy to launch generic ‘Lipitor’ in US by November
09 Sep 2011
Ranbaxy Laboratories, India’s largest drugmaker, will launch a generic version of Lipitor, the world’s top-selling cholesterol control drug, in the US by November
.webp)
